- Conditions
- Diabetes Mellitus, Type 1, Hypoglycemia, Islet Cell Transplantation, Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D), Severe Hypoglycemia, Xenotransplantation, Hypoglycemic Episode, Islet Transplantation in Diabetes Mellitus Type 1, Glucose Metabolism Disorders (Including Diabetes Mellitus), Immune System Diseases, Autoimmune Diseases, Metabolic Disease
- Interventions
- OPF-310
- Combination Product
- Lead sponsor
- Otsuka Pharmaceutical Factory, Inc.
- Industry
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 22, 2026, 4:18 AM EDT